期刊文献+

我院2012-2014年静脉用化疗药品用量分析

Analysis of the application of intravenous chemotherapy drugs in our hospital from 2012 to 2014
下载PDF
导出
摘要 目的 :分析2012-2014年我院静脉用化疗药品用量,了解近年肿瘤患者用药的主要特点及药品的应用情况,为静脉用化疗药品应用和药物经济学研究提供参考。方法 :对上海同济大学附属同济医院2012-2014年静脉用化疗药品的销售金额和用药频度(DDDs)等进行统计并分析。结果 :大类中,我院静脉用抗肿瘤药品中抗代谢类药物的使用金额和DDDs最大。单药中,培美曲塞每年的使用金额最大,甲氨蝶呤每年的DDDs最大。结论 :我院静脉用抗肿瘤化疗药物的用量稳步上升,使用品种朝着高效、低毒、价廉发展。 Object: To analyze the intravenous medication for tumor chemotherapy during 2012-2014 and understand the main characters for the medication of patients with tumor and the application of drugs in recent years, so as to provide a reference for the clinical medication and the study of pharmacoeconomics. Methods: The sales and defined daily doses(DDDs) for intravenous tumor chemotherapy drugs were statistically analyzed. Results: The sales and DDDs of anti-metabolic drugs are the greatest in the categories. The annual sales for drug pemetrexed are the greatest in individual drug and the annual DDDs for methotrexate are the greatest. Conclusion: The amount of intravenous anti-tumor chemotherapy drugs in our hospital is steadily increasing and the varieties used show a trends of efficient, low toxicity and low cost development.
出处 《上海医药》 CAS 2015年第17期51-54,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 静脉用化疗药 用量分析 用药频度 tumor chemotherapy drugs medication analysis DDDs
  • 相关文献

参考文献8

二级参考文献40

  • 1Li W Z, Fu W Z, Pei Y S, Sui Z. 2000 kN Multi-point forming press and its application to the manufacture of high-speed trains[A]. Advanced Technology of Plasticity Proceedings of the 7th ICTP[C], JAPAN,2002:979~984
  • 2全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 3赫捷,赵平,陈万青.2012年中国肿瘤登记年报[M].北京:军事医学科学出版社,2012.56-59.
  • 4Rosenberg B, van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode [J]. Nature, 1965, 205(4972): 698-699.
  • 5Rosenberg B, van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents [J]. Nature, 1969, 222(5191): 385-386.
  • 6Lippman A, Helson C, Helson L, et al. Clinical trials of cis-diamminedichloroplatinum (NSC-119875) [J]. Cancer Treatment Rep, 1973, 57(2): 191-200.
  • 7Cvitkovic S, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSCl19875) therapeutic index in an animal model [J]. Cancer, 1977, 39(4): 1357- 1361.
  • 8Einhorn L, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer [J]. Ann Intern Med, 1977, 87(3): 293-298.
  • 9Rossi A, di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small- cell lung cancer: the COCIS meta-analysis of individual patient data [J]. J Clin Oncol, 2012, 30(14): 1692-1698.
  • 10Alberto ME, Lucas MF, Pavelka M, et al. The second- generation anticancer drug nedaplatin: a theoretical investigation on the hydrolysis mechanism [J]. J Plays Chem B, 2009, 113(43): 14473-14479.

共引文献1742

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部